Physician profile
Muhammad A Malik
NPI 1679739411
$3,389.92
in general payments reported to CMS, 2019-2025
25 companies · $1,010 in 2025
The $1,010 reported for 2025 was more than what 78% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63.20 · 2020: $22.03 · 2021: $353 · 2022: $406 · 2023: $860 · 2024: $676 · 2025: $1,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,429 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,428.88 |
| Education | $116.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $620.51 | 2023-2025 | Accrufer |
| Travere Therapeutics, INC. | $450.38 | 2022-2024 | |
| Aurinia Pharma U.S., INC. | $286.84 | 2021-2025 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $234.59 | 2020-2025 | Jynarque |
| Amgen INC. | $184.72 | 2024-2025 | Krystexxa |
| Opko Pharmaceuticals, LLC | $175.07 | 2021-2025 | Rayaldee |
| Astrazeneca Pharmaceuticals LP | $169.44 | 2022-2024 | Farxiga |
| Horizon Therapeutics Plc | $150.49 | 2021-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $150.43 | 2024-2025 | |
| Glaxosmithkline, LLC. | $140.29 | 2021-2025 | Benlysta, Arexvy, Shingrix |
| Ani Pharmaceuticals, INC. | $124.99 | 2025 | Purified Cortrophin Gel |
| Akebia Therapeutics INC | $102.29 | 2019-2024 | Auryxia, Vafseo |
| Fresenius USA Marketing, INC. | $97.49 | 2023-2025 | Korsuva, Velphoro, Velphoro |
| Calliditas Therapeutics US INC. | $92.59 | 2022-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $79.82 | 2023-2025 | Acthar |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $73.29 | 2021-2023 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $70.97 | 2021-2023 | |
| Ardelyx, INC. | $67.83 | 2024-2025 | Ibsrela |
| Baxter Healthcare | $23.36 | 2022 | |
| Novo Nordisk INC | $18.99 | 2025 | Ozempic |
| Alnylam Pharmaceuticals INC. | $18.74 | 2021 | |
| Alexion Pharmaceuticals, INC. | $16.12 | 2022 | |
| Ascendis Pharma Endocrinology INC | $14.31 | 2025 | Yorvipath |
| Kyowa Kirin, INC. | $13.19 | 2024 | Crysvita |
| Cormedix INC. | $13.18 | 2024 | Defencath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.